UK biotechnology company TRIMTECH Therapeutics announced on Monday that it has entered into a strategic research collaboration, option and licence agreement with Biogen International GmbH, part of US biotechnology company Biogen Inc (NASDAQ:BIIB), to develop small molecule protein degraders targeting neurodegenerative diseases.
The collaboration will leverage TRIMTECH's proprietary TRIM21-based targeted protein degradation technology to discover and develop therapies targeting toxic protein aggregates associated with neurodegenerative conditions.
Under the agreement, TRIMTECH is eligible to receive up to USD32m in upfront and research milestone payments, with total potential payments of up to USD411m, plus royalties. If Biogen exercises its option, it will receive a global exclusive licence to the resulting degraders and assume responsibility for further development and commercialisation.
TRIMTECH's technology uses small molecule TRIMTAC and TRIMGLUE degraders designed to access the central nervous system and selectively break down toxic protein aggregates and oligomers implicated in neurodegenerative diseases.
Aelis Farma announces receipt of second positive safety recommendation for Down syndrome trial
Ambrosia Biosciences reports data on two oral small molecule programs at ObesityWeek 2026
Specialised Therapeutics' YONDELIS sarcoma therapy approved in Thailand
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Breakthrough T1D and Walgreens Foundation join forces to support the type 1 diabetes community
PAI Pharma acquires Nexus Pharmaceuticals
Innovent Biologics presents preclinical data for IL-6/TL1A bispecific antibody IAR177